Empagliflozin 25 mg Tablet

Product Overview

Empagliflozin 25 mg Tablet is a prescription medication formulated for the management of type 2 diabetes mellitus. Manufactured by Healing Pharma, India, each strip contains ten tablets delivering a consistent 25 milligram dose of the active ingredient. The product is packaged in strengths of 100, 200, or 300 tablets, providing flexible supply options for patients and clinicians. Designed for oral administration, the tablet is intended to be taken once daily, preferably with or without food, to support sustained glycemic control. Shipping typically occurs within six to fifteen days, depending on the destination.

What is Empagliflozin 25 mg Tablet

Empagliflozin belongs to the class of sodium‑glucose cotransporter‑2 (SGLT2) inhibitors. It functions by blocking the reabsorption of glucose in the kidneys, thereby promoting the excretion of excess glucose through urine. This mechanism helps lower blood glucose levels without stimulating insulin secretion. The 25 mg strength is the most commonly prescribed dose for adults with type 2 diabetes who require additional pharmacologic support beyond lifestyle modification. The medication is marketed under the brand name Empagliflozin and is identified by the active ingredient Empagliflozin, although the manufacturer lists “nan” as the active ingredient placeholder; the therapeutic component is fully characterized as Empagliflozin.

Uses and Benefits

The primary indication for Empagliflozin 25 mg Tablet is the improvement of glycemic control in adults with type 2 diabetes. Clinical studies have demonstrated that regular use can reduce hemoglobin A1c by approximately 0.5 to 1.0 percent, a clinically meaningful threshold. In addition to glucose lowering, the drug provides cardiovascular risk reduction, particularly in patients with established heart disease or those at high risk for hospitalization due to heart failure. The medication is also associated with modest weight loss, which can further aid diabetes management. Health care providers may consider Empagliflozin as part of a comprehensive treatment plan that includes diet, exercise, and other antidiabetic agents.

How It Works

Empagliflozin exerts its effect by selectively inhibiting the SGLT2 transporter located on the luminal surface of renal proximal tubule cells. Under normal physiological conditions, SGLT2 reabsorbs filtered glucose back into the bloodstream, contributing to hyperglycemia when dysregulated. By blocking this pathway, the drug prevents reabsorption, leading to an approximate urinary glucose excretion of 80 to 100 grams per day. This caloric loss translates into a reduction in plasma glucose concentrations and improves insulin sensitivity. The renal hemodynamic response also decreases intraglomerular pressure, offering potential renoprotective benefits in diabetic patients.

Dosage Guidelines

Standard dosing for Empagliflozin 25 mg Tablet consists of one tablet taken orally once daily, preferably at the same time each day. The tablet may be swallowed whole with a full glass of water and does not require administration with meals. For patients with renal impairment, dose adjustment is recommended when the estimated glomerular filtration rate (eGFR) falls below 45 mL/min/1.73 m², as the drug’s efficacy diminishes in advanced kidney disease. Physicians should initiate therapy at the 25 mg strength and may consider dose escalation to 10 mg if further glycemic control is needed, though the 25 mg dose is the maximum approved strength for most indications. Adherence to the prescribed regimen is essential to achieve optimal therapeutic outcomes.

Side Effects

Like all pharmaceutical agents, Empagliflozin 25 mg Tablet can be associated with adverse events. The most commonly reported side effects include urinary tract infections, genital mycotic infections, and increased urination. Less frequent but clinically significant events comprise volume depletion, hypotension, and ketoacidosis, particularly in circumstances of reduced fluid intake or concurrent insulin therapy. Rarely, patients may experience hypersensitivity reactions such as rash or angioedema. Healthcare providers should monitor patients for signs of dehydration or renal function decline, especially during the first few weeks of treatment. For a comprehensive list of side effects, refer to reputable drug databases such as Drugs.com or consult the FDA prescribing information.

Warnings and Precautions

Patients should be advised to maintain adequate hydration to reduce the risk of volume depletion and associated hypotension. Empagliflozin is contraindicated in individuals with a history of hypersensitivity to the drug or any of its inactive ingredients. Caution is warranted in patients with severe renal impairment (eGFR < 30 mL/min/1.73 m²) due to insufficient data on safety and efficacy. The medication should be used with care in those with a history of diabetic ketoacidosis, as the risk may increase under certain stressors. Concomitant use with other antidiabetic agents that increase hypoglycemia risk requires dose adjustment to avoid low blood sugar events. Pregnant or breastfeeding women should not use Empagliflozin without medical supervision. For detailed safety information, consult the NIH resource at NIH or the FDA’s drug label database.

FAQs

Q: Can Empagliflozin 25 mg Tablet be taken by patients with type 1 diabetes? A: The medication is approved only for type 2 diabetes. Use in type 1 diabetes is not recommended because of the increased risk of ketoacidosis.

Q: How long does it take to see a reduction in blood sugar levels? A: Most patients observe a measurable decline in fasting glucose within one to two weeks of consistent daily dosing, with further improvements over subsequent months.

Q: Is it safe to use Empagliflozin alongside insulin or sulfonylureas? A: Yes, but clinicians must adjust the dose of the accompanying medication to lower the probability of hypoglycemia, especially when insulin doses are high.

Q: Does the drug cause weight loss? A: Empagliflozin can lead to modest weight reduction, typically ranging from 2 to 4 kilograms over six months, primarily due to caloric loss through urine.

Q: Where can I find the official prescribing information? A: The complete FDA label and additional regulatory details are available at FDA Drugs and the NIH’s drug information portal.

Related Products

• Varditra 20 Mg (Vardenafil)
• Varditra 40 Mg (Vardenafil)
• Varditra 60 mg (Vardenafil)
• Tastylia 40 Mg (Tadalafil)
• Tastylia 60 mg (Tadalafil)
• Tastylia 80 mg (Tadalafil)
• Dapoforce 30 mg (Dapoxetine)
• Dutasteride 0.5 mg Softgel Capsule (Dutaheal)
• Glucagen Injection (Glucagon)
• Jardiance 10 mg (Empagliflozin)
• Canaprin 5000iu (Heparin Sodium)
• Minoxidil 5% Lotion (Minoxidil)